FOLH1 and prostate carcinoma: The overexpression of PSMA in prostate cancer, which in cell lines has been demonstrated to increase angiogenesis, and enhance metabolism of polyglutamated folates and uptake of monoglutamated folates, thus imparting a proliferative advantage [9], may be similarly exploited.